Literature DB >> 3358796

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

F C Arnett1, S M Edworthy, D A Bloch, D J McShane, J F Fries, N S Cooper, L A Healey, S R Kaplan, M H Liang, H S Luthra.   

Abstract

The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA). The new criteria are as follows: 1) morning stiffness in and around joints lasting at least 1 hour before maximal improvement; 2) soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician; 3) swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or wrist joints; 4) symmetric swelling (arthritis); 5) rheumatoid nodules; 6) the presence of rheumatoid factor; and 7) radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints. Criteria 1 through 4 must have been present for at least 6 weeks. Rheumatoid arthritis is defined by the presence of 4 or more criteria, and no further qualifications (classic, definite, or probable) or list of exclusions are required. In addition, a "classification tree" schema is presented which performs equally as well as the traditional (4 of 7) format. The new criteria demonstrated 91-94% sensitivity and 89% specificity for RA when compared with non-RA rheumatic disease control subjects.

Entities:  

Mesh:

Year:  1988        PMID: 3358796     DOI: 10.1002/art.1780310302

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  2000 in total

1.  Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE).

Authors:  M Kawano; T Seya; I Koni; H Mabuchi
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection.

Authors:  B S Tzang; T Y Chen; T C Hsu; Y C Liu; G J Tsay
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

3.  Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis.

Authors:  T Uhlig; T K Kvien; J L Jensen; T Axéll
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

4.  Ultrasonography in the evaluation of bone erosions.

Authors:  W Grassi; E Filippucci; A Farina; F Salaffi; C Cervini
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

Review 5.  Anti-TNF agents for rheumatoid arthritis.

Authors:  H E Seymour; A Worsley; J M Smith; S H Thomas
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 6.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

7.  Sialyl Lewis(x) expression on IgG in rheumatoid arthritis and other arthritic conditions: a preliminary study.

Authors:  M T Goodarzi; J S Axford; S S Varanasi; A Alavi; G Cunnane; O Fitzgerald; G A Turner
Journal:  Glycoconj J       Date:  1998-12       Impact factor: 2.916

8.  Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA).

Authors:  M M Luchetti; G Piccinini; A Mantovani; G Peri; C Matteucci; G Pomponio; M Fratini; P Fraticelli; P Sambo; C Di Loreto; A Doni; M Introna; A Gabrielli
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

9.  Nosology and causal necessity; the relation between defining a disease and discovering its necessary cause.

Authors:  F J Flier; P F de Vries Robbé
Journal:  Theor Med Bioeth       Date:  1999-12

10.  Development of the antinuclear and anticytoplasmic antibody consensus panel by the Association of Medical Laboratory Immunologists.

Authors:  K James; A B Carpenter; L Cook; R Marchand; R M Nakamura
Journal:  Clin Diagn Lab Immunol       Date:  2000-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.